AstraZeneca

AstraZeneca OCF Margin

The Operating Cash Flow Margin of AstraZeneca (AZN.L) as of Oct 18, 2026 is 24.81 %. In the previous year, Operating Cash Flow Margin was 22.40 % — a change of 10.76% (higher).

OCF Margin

24.81 %

YoY

10.76%

Last updated:

Operating Cash Flow Margin of AstraZeneca is 2025 24.81 % . Operating Cash Flow Margin of AstraZeneca was 2024 22.40 % . It decreases by 10.76% higher compared to the previous year.

The AstraZeneca OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2018
12.48 USD
Jan 1, 2019
12.12 USD
Jan 1, 2020
16.40 USD
Jan 1, 2021
16.07 USD
Jan 1, 2022
22.16 USD
Jan 1, 2023
22.21 USD
Jan 1, 2024
22.40 USD
Jan 1, 2025
24.81 USD
The AstraZeneca OCF Margin history
YEAROCF MarginYoY
24.81 %+10.76%
22.40 %+0.88%
22.21 %+0.20%
22.16 %+37.92%
16.07 %-1.99%
16.40 %+35.29%
12.12 %-2.86%
12.48 %-18.23%
15.26 %-22.99%
19.81 %+42.60%
13.89 %-49.04%
27.27 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AstraZeneca Stock analysis

What does AstraZeneca do? AstraZeneca PLC is a globally operating pharmaceutical company with its headquarters in England. The company was founded in 1999 through the merger of the Swedish company Astra AB and the British Zeneca Group PLC. Today, AstraZeneca employs more than 70,000 people and operates in over 100 countries. AstraZeneca specializes in the development, manufacturing, and marketing of pharmaceutical products. The company focuses primarily on oncology, cardiovascular and metabolic diseases, respiratory diseases, and autoimmune diseases. AstraZeneca is divided into various business segments. The oncology segment is a major focus of the company. Here, medications for various types of cancer are developed and manufactured. One particularly well-known product is the breast cancer medication Tamoxifen. In the cardiovascular and metabolic diseases segment, AstraZeneca offers various medications for heart and circulatory diseases as well as diabetes. One of the most well-known medications is Crestor, which is used to lower cholesterol levels. Another important area for AstraZeneca is respiratory diseases. Medications for the treatment of asthma and chronic obstructive pulmonary disease (COPD) are developed and manufactured here. The medication Pulmicort is particularly well-known among asthma patients. Finally, AstraZeneca is also active in the field of autoimmune diseases. Medications against lupus erythematosus and rheumatoid arthritis are developed and manufactured here. AstraZeneca strives to improve healthcare worldwide through research and development of new medications. The company works closely with universities and research institutions and invests billions of dollars annually in research and development. AstraZeneca also pursues a sustainable business strategy and emphasizes acting environmentally and socially responsibly. The company is committed to reducing CO2 emissions and minimizing waste production. Over the years, AstraZeneca has received numerous awards and prizes, including the Sunday Times Innovation Award of the Decade, the Fierce Biotech Award for the medication Tagrisso, and the Prix Galien USA Award for Crestor. AstraZeneca aims to develop innovative medications that improve the lives of patients and advance healthcare worldwide. The company believes in a sustainable business strategy and actively promotes environmental and social responsibility. AstraZeneca will remain an important player in the global pharmaceutical industry in the future. AstraZeneca is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AstraZeneca stock

Operating Cash Flow Margin of AstraZeneca is 24.81 % in 2025.

Operating Cash Flow Margin of AstraZeneca changed from 22.40 % to 24.81 %, representing a 10.76% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin AstraZeneca since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's AstraZeneca with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — AstraZeneca

All Key Metrics — AstraZeneca